Via360 Expands Canal-Based MIGS Options

1

The Via360 surgical system combines canaloplasty and trabeculotomy, offering enhanced control over viscoelastic delivery during glaucoma surgery.
2

The system received FDA 510(k) clearance in February 2025 for controlled viscoelastic delivery and trabecular meshwork incisions.
3

ActiveInject technology allows surgeons to deliver viscoelastic on demand, independent of catheter movement, enhancing procedural efficiency.
4

The device's microcatheter can advance 360° within Schlemm's canal, facilitating targeted treatment of outflow resistance.
5

Clinical experience indicates the Via360 system effectively reduces intraocular pressure and medication burden in patients with various glaucoma types.

1